Delivery Order HHSN261201500038I-HHSN26100011
Award Date 9/15/17
Potential Completion Date 6/14/20
Potential Value $521K
Federal Agency
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Oklahoma City, OK 73104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed price Delivery Order awarded by the National Cancer Institute (NCI) to the University of Oklahoma (OU) for the "Prevention of Colorectal Cancer by ONC201" project. The contract, which is part of the NCI's "PREVENT Cancer Program", has a period of performance from September 2016 to September 2018 and a ceiling value of $221,345. The work is focused on preclinical cancer prevention research, specifically evaluating the efficacy of the drug ONC201 for...
- This is a firm fixed-price delivery order contract awarded by the National Cancer Institute, part of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ of Oklahoma Health Sciences Center Division. The $628,343 contract is for research and development related to the Preclinical Prevention Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers. This work is not set aside for small businesses. The University of Oklahoma, acting...
- This is a $819,519.17 cost-reimbursement delivery order awarded by the National Cancer Institute, a civilian agency of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The order is placed under the Preclinical Agent Development Assays 2012-2016 contract vehicle and supports the development of inhibitors for MPGES-1 and 5-LOX proteins for use as colon cancer chemopreventive agents. This work is part of the agency's...
- This is a delivery order award under the National Cancer Institute's PREVENT Preclinical Drug Development Program, a $149,995,000 indefinite-delivery, indefinite-quantity (IDIQ) contract. The award, valued at $878,817.03, is for a task order titled "Preventing Colorectal Cancer Using TRAIL-Inducing ONC201 Alone or in Combination with NSAID." The prime contractor is the University of Oklahoma Health Sciences Center, a state-funded public research university with significant federal...
- The University of Oklahoma Health Sciences Center (OUHSC) was awarded a $909,993.85 firm fixed-price delivery order by the National Cancer Institute on September 21, 2020, for the evaluation of two different classes of compounds—STAT3 inhibitors and selective estrogen receptor modulators (SERMs)—for the prevention of urinary bladder cancer. This delivery order is issued under the PREVENT Cancer Preclinical Drug Development Program, an expansive National Cancer Institute Indefinite...
- This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU) for "TARGETING CCK2R FOR PANCREATIC CANCER PREVENTION". The $474,197.46 contract is part of the NCI's Preclinical Agent Development Assays 2012-2016 program, which focuses on preclinical in vitro and in vivo agent development assays. The award does not have a set-aside designation. As...
- The National Cancer Institute awarded a $982,258 firm fixed price delivery order to the University of Oklahoma Health Sciences Center to support preclinical drug development research focused on preventing lung adenocarcinoma using ONC201, a TRAIL-inducing agent. The task order was issued under the PREVENT Cancer Preclinical Drug Development Program and has an ultimate completion date of September 7, 2026. The work will be performed in Oklahoma City, Oklahoma. This delivery order was awarded...
- This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the University of Oklahoma Health Sciences Center Division. The contract is part of the NCI's "PREVENT Cancer Program (PREVENT)" and covers a "CONTRACT ORIENTATION AND KICK-OFF MEETING" with a period of performance from September 22, 2015 to December 31, 2015. The contract has a ceiling value of $4,217.44 and is a Delivery Order...
- This is a federal contract award for $686,894.80 by the National Cancer Institute (NCI) under the Preclinical Agent Development Assays 2012-2016 program. The award was made to the University of Oklahoma (OU) to test the efficacy of aspirin and omeprazole for colorectal cancer chemoprevention. This was a delivery order contract with a cost-no-fee pricing type, and there was no set-aside designation. OU is a public research university that provides a range of medical research, healthcare, and...
- This federal contract award was issued by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU). The $633,898 firm fixed price delivery order is part of NCI's "Preclinical Agent Development Assays 2012-2016" indefinite delivery contract and supports research on the use of the drug naproxen for the prevention of colorectal cancer. The contract does not have a small business set-aside...